english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2021 > The Prescrire Drug Awards for 2021 > 2021 Drug Awards > Vaxzevria° (covid-19 vaccine ChAdOx1-S): on the Honours List at the 2021 Prescrire Drug Awards

The Prescrire Awards for 2021

The Prescrire Drug Awards for 2021

The Prescrire Drug Awards for 2021
Vaxzevria° (covid-19 vaccine ChAdOx1-S): on the Honours List at the 2021 Prescrire Drug Awards

Le Palmarès des Médicaments Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations.

• VAXZEVRIA° (covid-19 vaccine ChAdOx1-S) – AstraZeneca 

For active immunisation against the virus Sars-CoV-2 to prevent covid-19 disease (Prescrire Int n° 229).

Covid­-19 vaccines Ad26.CoV2­-S and ChAdOx1-­S: when mRNA vaccines are not available.

In addition to the mRNA covid-19 vaccines, two viral vector covid-19 vaccines were authorised in the European Union in 2021: covid-19 vaccine Ad26.CoV2-S (Covid-19 Vaccine Janssen°, Janssen-Cilag) and covid-19 vaccine ChAdOx1-S (Vaxzevria°, AstraZeneca).

In trials conducted in tens of thousands of people in 2020 during the pandemic, these two vaccines reduced the risk, in the short term, of developing symptomatic covid-19 and of hospitalisation for covid-19. One major unknown is how effective they will be against any new Sars-CoV-2 variants that emerge.

The short-term adverse effects of these two vaccines are those common to most vaccines, mainly frequent local and systemic reactions. Rare but serious thromboses, with thrombocytopenia or haemorrhage, were identified as adverse effects during the vaccination campaigns. As with the mRNA covid-19 vaccines, unknowns persist over their long-term adverse effects.

In practice, these thromboses are sufficiently serious to position these two vaccines, as of 2021, as second-tier options after mRNA covid-19 vaccines. They were particularly useful in 2021 in geographical regions where logistics, availability or cost prevented access to mRNA covid-19 vaccines, and made their use unfeasible. These two vaccines, which constitute an additional arm in the fight against the covid-19 epidemic, therefore feature on this year's Honours List.

A Pilule d'Or (Golden Pill) is granted to drugs that represent a major therapeutic advance in a field in which no treatment was previously available. Drugs included on the Honours List constitute a clear advance for some patients compared with existing therapeutic options, albeit with limitations. Drugs deemed "Noteworthy" provide a modest improvement in patient care.
SEE: > About the Prescrire Drug Awards for 2021

Le Palmarès de l'information
> The Prescrire Drug Awards for 2021

Download the full article:

 FREE  "The Prescrire Awards for 2021" Prescrire International 2022; 31 (235): 79-82. (pdf, free)


Back to "The Prescrire Awards for 2021">

©Prescrire February 2022
Share Share on Facebook Share on Twitter


Enjoy full access to Prescrire International, and support independent information